Teva Pharmaceutical Industries Limited ( (TEVA) ) has released its Q3 earnings. Here is a breakdown of the information Teva Pharmaceutical Industries Limited presented to its investors.
Pick the best stocks and maximize your portfolio:
- Discover top-rated stocks from highly ranked analysts with Analyst Top Stocks!
- Easily identify outperforming stocks and invest smarter with Top Smart Score Stocks
Teva Pharmaceutical Industries Ltd. is a global leader in pharmaceuticals, specializing in generics and innovative medicines, operating in over 58 markets. In its third quarter of 2024, Teva reported strong financial results with a revenue increase of 13% to $4.3 billion, driven by its generics and innovative portfolio. Key highlights include a 28% growth in AUSTEDO revenues in the US, a 21% increase in AJOVY global revenues, and a promising pipeline with upcoming results for new products. Despite a GAAP loss per share of $0.39, Teva’s non-GAAP diluted EPS was $0.69, and the company raised its full-year financial outlook. Moving forward, Teva’s management remains optimistic, focusing on its ‘Pivot to Growth’ strategy to further enhance its product pipeline and market presence while addressing challenges such as currency fluctuations and legal settlements.
